Cushing’s Awareness Patient Day

Saturday, February 1st, 2014

San Francisco, California

Hosted by Kate Tully, R.N. and Katherine Waidner, R.N.
Cushing’s Patient Advocates – Corcept Therapeutics

Agenda and details to follow

The day will focus on endogenous Cushing’s, a condition caused by high cortisol in your body.

The day will not cover exogenous Cushing’s caused by steroids taken for various health conditions including asthma, arthritis or lupus.

Questions about Korlym?

Corcept is providing a nurse to help with insurance and other topics.

If you want a person to talk with her contact info is:

Kate Tully, R.N., B.S.N.
(650) 688-2804
ktully@corcept.com

Cushing’s Patient Advocate
Corcept Therapeutics
149 Commonwealth Drive
Menlo Park, CA 94025

More information about Korlym at http://www.korlym.com

TODAY is the LAST DAY...

...To support Cushing's patients by only clicking a link. Click here to make a difference!

Feel free to share the link around, click more than once, post to Twitter, LinkedIn and Facebook.  Every click is worth $5.00 to Cushing's organizations which support patients.

Thank you for your support!

Support Cushing's ...With A Click.
From Corcept, the makers of Korlym:

Corcept Therapeutics will donate $5 for every person who clicks to support people with Cushing's. Corcept has jump-started the effort to build awareness and support with a $15,000 contribution to provide support through the Cushing's Support and Research Foundation and Cushing's Help.
With your support, we can aim even higher!*
Take part...and spread the word.
*Donations up to $30,000. Program ends April 20, 2012

Click here to make a difference!

It's Cushing's Awareness Day! Help Cushing's Help at No Cost to You

 

Support Cushing's ...With A Click.

From Corcept, the makers of Korlym:

They say: "Corcept Therapeutics will donate $5 for every person who clicks to support people with Cushing's. Corcept has jump-started the effort to build awareness and support with a $15,000 contribution to provide support through the Cushing's Support and Research Foundation and Cushing's Help.

With your support, we can aim even higher!*

Take part...and spread the word.

*Donations up to $30,000. Program ends April 20, 2012"

Click here to make a difference!

 

A Simple Mouse Click to Help Support Cushing's Awareness Day!

Support Cushing's ...With A Click.

From Corcept, the makers of Korlym:

They say: "Corcept Therapeutics will donate $5 for every person who clicks to support people with Cushing's. Corcept has jump-started the effort to build awareness and support with a $15,000 contribution to provide support through the Cushing's Support and Research Foundation and Cushing's Help. With your support, we can aim even higher!*

Take part...and spread the word.

*Donations up to $30,000. Program ends April 20, 2012"

Click here to make a difference!

Do We Feel Bad for the Drug Reps?

Pharma-watchers know that rare diseases are all the rage these days. With primary-care blockbusters falling to generic competition, drugmakers are zeroing in on ultra-expensive treatments for conditions that affect only a few hundred patients, rather than millions of them. And companies don't just benefit from the ability to command high prices. They also save on sales reps and ad campaigns.

For pharma sales reps, it may seem like adding insult to injury, after the past several years of mass layoffs. But as Medical Marketing & Media reports, companies won't be staffing up much to launch rare-disease drugs. Take Corcept Therapeutics ($CORT), now preparing to roll out its Cushing's syndrome drug Korlym. "I don't have to hire an army of sales reps," Corcept VP Steven Lo tellsMM&M.

Instead, Corcept will target just 300 endocrinologists to reach the 5,000 or so Cushing's patients Korlym could benefit (of the total 20,000 in the U.S.). Those 300 doctors handle 70% of Cushing's cases in the U.S., Lo says. Corcept will send out medical liaisons, supported by professional advertising and CME. An agency that specializes in orphan and specialty meds will handle advertising to patients and online.

Korlym will no doubt benefit from another advantage that rare-disease drugs usually enjoy: They have no competitors. Cushing's patients who haven't benefited from surgery don't have other drugs to turn to. It will be Korlym or nothing. At what price has yet to be seen; Corcept hasn't yet said how much it will charge for the drug.

Read more: Rare-disease drugs won't help out-of-work pharma reps - FiercePharma

Dr. Theodore Friedman Returns to Answer Our Questions

Have questions about the new Korlym? How about Korlym vs ketoconazole? About medical vs surgical treatment for Cushing's.

 
Ask Dr. Theodore Friedman.

 

 

Theodore C. Friedman, M.D., Ph.D. has opened a private practice, specializing in treating patients with adrenal, pituitary, thyroid and fatigue disorders. Dr. Friedman has privileges at Cedars-Sinai Medical Center and Martin Luther King Medical Center. His practice includes detecting and treating hormone imbalances, including hormone replacement therapy. Dr. Friedman is also an expert in diagnosing and treating pituitary disorders, including Cushings disease and syndrome.

Dr. Friedman's career reflects his ongoing quest to better understand and treat endocrine problems. With both medical and research doctoral degrees, he has conducted studies and cared for patients at some of the country's most prestigious institutions, including the University of Michigan, the National Institutes of Health, Cedars-Sinai Medical Center, and UCLA's Charles Drew University of Medicine and Science.

Read Dr. Friedman's First Guest Chat, November 11, 2003. 
Read Dr. Friedman's Second Guest Chat, March 2, 2004. 

Listen to Dr. Friedman First Live Voice Interview, January 29, 2009. 
Listen to Dr. Friedman Second Live Voice Interview, March 12, 2009. 
Listen to Dr. Friedman Third Live Voice Interview, February 13, 2011.

 

 

Listen live at http://www.blogtalkradio.com/cushingshelp/2012/03/13/questions-about-medical-therapies-for-cushings

Call in to ask your question at 

(646) 200-0162

This interview will be archived afterwards at the same link and on iTunes Cushie Podcasts 

Conference call about Korlym

Korlym was approved February 17th, 2012 for persistant Cushing's. More information here.

Corcept will hold a conference call on Tuesday, February 21, 2012 at 9:00 a.m. Eastern Time (6:00 a.m. Pacific Time) to discuss this announcement. To participate in the live call please dial 1-800-264-7882 from the United States or +1-847-413-3708 internationally. The pass code is 31838602. Please dial in approximately 10 minutes before the start of the call.

A replay of the conference call will be available through March 6, 2012 at 1-888-843-7419 from the United States and +1-630-652-3042 internationally. The pass code is 31838602.